a31907aa1f
- Remove app_v2.py (consolidated into pathways_app.py), fix __init__ import - Add DimSearchTerm.csv, drug_indication_clusters.csv, drug_snomed_mapping_enriched.csv as reference data for SNOMED-based indication matching - Add snomed_indication_mapping_query.sql (source for embedded cluster mapping) - Update DESIGN_SYSTEM.md, RALPH_PROMPT.md, ralph.ps1, uv.lock
7.8 MiB
7.8 MiB
| 1 | Drug | Indication | TA_ID | Search_Term | SNOMEDCode | SNOMEDDescription | CleanedDrugName | PrimaryDirectorate | AllDirectorates |
|---|---|---|---|---|---|---|---|---|---|
| 2 | ABATACEPT | Psoriatic arthritis after DMARDs | TA568 | psoriatic arthritis | 156370009 | Psoriatic arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 3 | ABATACEPT | Psoriatic arthritis after DMARDs | TA568 | psoriatic arthritis | 239802003 | Juvenile psoriatic arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 4 | ABATACEPT | Psoriatic arthritis after DMARDs | TA568 | psoriatic arthritis | 239803008 | Juvenile psoriatic arthritis with psoriasis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 5 | ABATACEPT | Psoriatic arthritis after DMARDs | TA568 | psoriatic arthritis | 239812005 | Psoriatic arthritis with distal interphalangeal joint involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 6 | ABATACEPT | Psoriatic arthritis after DMARDs | TA568 | psoriatic arthritis | 430543001 | Family history of psoriasis with psoriatic arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 7 | ABATACEPT | Psoriatic arthritis after DMARDs | TA568 | psoriatic arthritis | 1036471000000109 | Psoriatic Arthritis Impact of Disease 9 questionnaire score | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 8 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 9 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 10 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 11 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 12 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 13 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 14 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 15 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 16 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 17 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 18 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 19 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 20 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 21 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 22 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 23 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 24 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 25 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 26 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 27 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 28 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 29 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 30 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 31 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 32 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 33 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 34 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 35 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 36 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 37 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 38 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 39 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 40 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 41 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 42 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 43 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 44 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 45 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 46 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 47 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 48 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 49 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 50 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 51 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 52 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 53 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 54 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 55 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 56 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 57 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 58 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 59 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 60 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 61 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 62 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 63 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 64 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 65 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 66 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 67 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 68 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 69 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 70 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 71 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 72 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 73 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 74 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 75 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 76 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 77 | ABATACEPT | Rheumatoid arthritis | TA141 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 78 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 79 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 80 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 81 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 82 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 83 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 84 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 85 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 86 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 87 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 88 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 89 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 90 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 91 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 92 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 93 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 94 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 95 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 96 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 97 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 98 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 99 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 100 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 101 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 102 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 103 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 104 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 105 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 106 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 107 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 108 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 109 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 110 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 111 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 112 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 113 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 114 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 115 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 116 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 117 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 118 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 119 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 120 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 121 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 122 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 123 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 124 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 125 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 126 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 127 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 128 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 129 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 130 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 131 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 132 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 133 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 134 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 135 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 136 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 137 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 138 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 139 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 140 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 141 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 142 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 143 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 144 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 145 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 146 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 147 | ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 148 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 149 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 150 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 151 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 152 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 153 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 154 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 155 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 156 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 157 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 158 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 159 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 160 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 161 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 162 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 163 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 164 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 165 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 166 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 167 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 168 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 169 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 170 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 171 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 172 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 173 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 174 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 175 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 176 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 177 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 178 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 179 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 180 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 181 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 182 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 183 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 184 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 185 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 186 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 187 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 188 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 189 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 190 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 191 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 192 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 193 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 194 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 195 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 196 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 197 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 198 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 199 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 200 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 201 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 202 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 203 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 204 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 205 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 206 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 207 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 208 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 209 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 210 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 211 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 212 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 213 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 214 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 215 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 216 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 217 | ABATACEPT IN COMBINATION WITH METHOTREXATE | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 218 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 219 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 220 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 221 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 222 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 223 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 224 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 225 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 226 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 227 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 228 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 229 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 230 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 231 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 232 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 233 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 234 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 235 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 236 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 237 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 238 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 239 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 240 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 241 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 242 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 243 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 244 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 245 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 246 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 247 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 248 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 249 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 250 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 251 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 252 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 253 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 254 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 255 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 256 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 257 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 258 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 259 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 260 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 261 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 262 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 263 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 264 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 265 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 266 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 267 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 268 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 269 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 270 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 271 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 272 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 273 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 274 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 275 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 276 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 277 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 278 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 279 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 280 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 281 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 282 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 283 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 284 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 285 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 286 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 287 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate | TA234 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 288 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 289 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 290 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 291 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 292 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 293 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 294 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 295 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 296 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 297 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 298 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 299 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 300 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 301 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 302 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 303 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 304 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 305 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 306 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 307 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 308 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 309 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 310 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 311 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 312 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 313 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 314 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 315 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 316 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 317 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 318 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 319 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 320 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 321 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 322 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 323 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 324 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 325 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 326 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 327 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 328 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 329 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 330 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 331 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 332 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 333 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 334 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 335 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 336 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 337 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 338 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 339 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 340 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 341 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 342 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 343 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 344 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 345 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 346 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 347 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 348 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 349 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 350 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 351 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 352 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 353 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 354 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 355 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 356 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 357 | ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE) | Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate | TA280 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 358 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 359 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 360 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 361 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 362 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 363 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 364 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 365 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 366 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 367 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 368 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 369 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 370 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 371 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 372 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 373 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 374 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 375 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 376 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 377 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 378 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 379 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 380 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 381 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 382 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 383 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 384 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 385 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 386 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 387 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 388 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 389 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 390 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 391 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 392 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 393 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 394 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 395 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 396 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 397 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 398 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 399 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 400 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 401 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 402 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 403 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 404 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 405 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 406 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 407 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 408 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 409 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 410 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 411 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 412 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 413 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 414 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 415 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 416 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 417 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 418 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 419 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 420 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 421 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 422 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 423 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 424 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 425 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 426 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 427 | ABATACEPT WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 428 | ABATECEPT | Treating juvenile idiopathic arthritis | TA373 | juvenile idiopathic arthritis | 410798004 | Oligoarticular juvenile idiopathic arthritis | ABATECEPT | RHEUMATOLOGY | RHEUMATOLOGY|PAEDIATRICS |
| 429 | ABATECEPT | Treating juvenile idiopathic arthritis | TA373 | juvenile idiopathic arthritis | 16044751000119106 | Juvenile idiopathic arthritis, polyarthritis | ABATECEPT | RHEUMATOLOGY | RHEUMATOLOGY|PAEDIATRICS |
| 430 | ABCIXIMAB | Acute coronary syndromes | TA047 | acute coronary syndrome | 837091000000100 | H/O acute coronary syndrome | ABCIXIMAB | CARDIOLOGY | CARDIOLOGY |
| 431 | ABCIXIMAB (INTRAVENOUS) | Acute coronary syndromes | TA012 | acute coronary syndrome | 837091000000100 | H/O acute coronary syndrome | ABCIXIMAB | CARDIOLOGY | CARDIOLOGY |
| 432 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 134405005 | Suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 433 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 160287004 | FH: Breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 434 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 268547008 | Screening for breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 435 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 405823003 | Breast cancer 1, early onset gene mutation carrier detection test | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 436 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 429740004 | Family history of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 437 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 431330007 | Family history of breast cancer 1 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 438 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 431331006 | Family history of breast cancer 2 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 439 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 706970001 | TNBC - Triple-negative breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 440 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 94361000000105 | Breast cancer detected by national screening programme | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 441 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 143691000119102 | Family history of breast cancer gene mutation in first degree relative | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 442 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 276341000000100 | Fast track referral for suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 443 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 382431000000103 | Seen in fast track suspected breast cancer clinic | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 444 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 836761000000105 | National Cancer Institute breast cancer risk assessment tool | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 445 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 838351000000107 | Education about risk of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 446 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 874291000000100 | QCancer breast cancer risk | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 447 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 895171000000104 | Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 448 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 919701000000100 | No FH of breast cancer meeting NICE CG164 referral criteria | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 449 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 1034381000000107 | Discharge from secondary care breast cancer service | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 450 | ABEMACICLIB | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA579 | breast cancer | 1035841000000108 | Lymphoedema following breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 451 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 134405005 | Suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 452 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 160287004 | FH: Breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 453 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 268547008 | Screening for breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 454 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 405823003 | Breast cancer 1, early onset gene mutation carrier detection test | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 455 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 429740004 | Family history of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 456 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 431330007 | Family history of breast cancer 1 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 457 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 431331006 | Family history of breast cancer 2 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 458 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 706970001 | TNBC - Triple-negative breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 459 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 94361000000105 | Breast cancer detected by national screening programme | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 460 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 143691000119102 | Family history of breast cancer gene mutation in first degree relative | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 461 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 276341000000100 | Fast track referral for suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 462 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 382431000000103 | Seen in fast track suspected breast cancer clinic | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 463 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 836761000000105 | National Cancer Institute breast cancer risk assessment tool | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 464 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 838351000000107 | Education about risk of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 465 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 874291000000100 | QCancer breast cancer risk | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 466 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 895171000000104 | Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 467 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 919701000000100 | No FH of breast cancer meeting NICE CG164 referral criteria | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 468 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 1034381000000107 | Discharge from secondary care breast cancer service | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 469 | ABEMACICLIB | Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist | TA563 | breast cancer | 1035841000000108 | Lymphoedema following breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 470 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 134405005 | Suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 471 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 160287004 | FH: Breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 472 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | hormone receptor | 237521008 | Hypothyroidism due to thyroid stimulating hormone receptor blocking antibody | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 473 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 268547008 | Screening for breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 474 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 405823003 | Breast cancer 1, early onset gene mutation carrier detection test | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 475 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | hormone receptor | 417742002 | Hormone receptor positive tumour | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 476 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 429740004 | Family history of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 477 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 431330007 | Family history of breast cancer 1 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 478 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 431331006 | Family history of breast cancer 2 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 479 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | hormone receptor | 438628005 | Hormone receptor negative tumour | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 480 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 706970001 | TNBC - Triple-negative breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 481 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 94361000000105 | Breast cancer detected by national screening programme | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 482 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 143691000119102 | Family history of breast cancer gene mutation in first degree relative | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 483 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 276341000000100 | Fast track referral for suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 484 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | hormone receptor | 310871000000100 | Tumour hormone receptor status | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 485 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 382431000000103 | Seen in fast track suspected breast cancer clinic | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 486 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 836761000000105 | National Cancer Institute breast cancer risk assessment tool | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 487 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 838351000000107 | Education about risk of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 488 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 874291000000100 | QCancer breast cancer risk | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 489 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 895171000000104 | Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 490 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 919701000000100 | No FH of breast cancer meeting NICE CG164 referral criteria | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 491 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 1034381000000107 | Discharge from secondary care breast cancer service | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 492 | ABEMACICLIB WITH ENDOCRINE THERAPY | Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | breast cancer | 1035841000000108 | Lymphoedema following breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 493 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 134405005 | Suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 494 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 160287004 | FH: Breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 495 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 268547008 | Screening for breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 496 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 405823003 | Breast cancer 1, early onset gene mutation carrier detection test | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 497 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 429740004 | Family history of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 498 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 431330007 | Family history of breast cancer 1 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 499 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 431331006 | Family history of breast cancer 2 gene mutation | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 500 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 706970001 | TNBC - Triple-negative breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 501 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 94361000000105 | Breast cancer detected by national screening programme | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 502 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 143691000119102 | Family history of breast cancer gene mutation in first degree relative | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 503 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 276341000000100 | Fast track referral for suspected breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 504 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 382431000000103 | Seen in fast track suspected breast cancer clinic | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 505 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 836761000000105 | National Cancer Institute breast cancer risk assessment tool | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 506 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 838351000000107 | Education about risk of breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 507 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 874291000000100 | QCancer breast cancer risk | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 508 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 895171000000104 | Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 509 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 919701000000100 | No FH of breast cancer meeting NICE CG164 referral criteria | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 510 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 1034381000000107 | Discharge from secondary care breast cancer service | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 511 | ABEMACICLIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | breast cancer | 1035841000000108 | Lymphoedema following breast cancer | ABEMACICLIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 512 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 315268008 | Suspected prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 513 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 428262008 | H/O: prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 514 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 698470001 | Advice given about prostate cancer screening | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 515 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 712837004 | Active surveillance of prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 516 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 720007002 | Prostate cancer care review | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 517 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 31011000119107 | Prostate cancer screening declined | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 518 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 874211000000109 | QCancer prostate cancer risk | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 519 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 878401000000104 | No FH of prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 520 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 1000561000000108 | Urine PCA3 (prostate cancer antigen 3) targeted genetic test | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 521 | ABIRATERONE | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | prostate cancer | 1034421000000103 | Discharge from secondary care prostate cancer service | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 522 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 315268008 | Suspected prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 523 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 428262008 | H/O: prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 524 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 698470001 | Advice given about prostate cancer screening | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 525 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 712837004 | Active surveillance of prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 526 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 720007002 | Prostate cancer care review | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 527 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 31011000119107 | Prostate cancer screening declined | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 528 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 874211000000109 | QCancer prostate cancer risk | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 529 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 878401000000104 | No FH of prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 530 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 1000561000000108 | Urine PCA3 (prostate cancer antigen 3) targeted genetic test | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 531 | ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE) | Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen | TA259 | prostate cancer | 1034421000000103 | Discharge from secondary care prostate cancer service | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 532 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 315268008 | Suspected prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 533 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 428262008 | H/O: prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 534 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 698470001 | Advice given about prostate cancer screening | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 535 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 712837004 | Active surveillance of prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 536 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 720007002 | Prostate cancer care review | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 537 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 31011000119107 | Prostate cancer screening declined | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 538 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 874211000000109 | QCancer prostate cancer risk | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 539 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 878401000000104 | No FH of prostate cancer | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 540 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 1000561000000108 | Urine PCA3 (prostate cancer antigen 3) targeted genetic test | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 541 | ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE | Treating metastatic hormone-relapsed prostate cancer before chemotherapy | TA387 | prostate cancer | 1034421000000103 | Discharge from secondary care prostate cancer service | ABIRATERONE | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY |
| 542 | ABROCITINIB | Moderate to severe atopic dermatitis | TA814 | atopic dermatitis | 238542007 | Inverse pattern atopic dermatitis | ABROCITINIB | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 543 | ABROCITINIB | Moderate to severe atopic dermatitis | TA814 | atopic dermatitis | 238543002 | Discoid atopic dermatitis | ABROCITINIB | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 544 | ABROCITINIB | Moderate to severe atopic dermatitis | TA814 | atopic dermatitis | 238544008 | Erythrodermic atopic dermatitis | ABROCITINIB | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 545 | ABROCITINIB | Moderate to severe atopic dermatitis | TA814 | atopic dermatitis | 238545009 | Follicular atopic dermatitis | ABROCITINIB | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 546 | ABROCITINIB | Moderate to severe atopic dermatitis | TA814 | atopic dermatitis | 238546005 | Pruriginous atopic dermatitis | ABROCITINIB | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 547 | ABROCITINIB | Moderate to severe atopic dermatitis | TA814 | atopic dermatitis | 584621000000108 | Atopic dermatitis NOS | ABROCITINIB | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 548 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 786855003 | Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 549 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 786855003 | Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 550 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 863741000000108 | Clinical stage A chronic lymphocytic leukaemia | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 551 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 863741000000108 | Clinical stage A chronic lymphocytic leukaemia | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 552 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 863761000000109 | Clinical stage B chronic lymphocytic leukaemia | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 553 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 863761000000109 | Clinical stage B chronic lymphocytic leukaemia | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 554 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 863781000000100 | Clinical stage C chronic lymphocytic leukaemia | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 555 | ACALABRUTINIB | Chronic lymphocytic leukaemia | TA689 | chronic lymphocytic leukaemia | 863781000000100 | Clinical stage C chronic lymphocytic leukaemia | ACALABRUTINIB | CLINICAL HAEMATOLOGY | CLINICAL HAEMATOLOGY |
| 556 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 162930007 | On examination - ankylosing spondylitis chest deformity | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 557 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 239805001 | Juvenile ankylosing spondylitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 558 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 239810002 | Ankylosing spondylitis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 559 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 239811003 | Ankylosing spondylitis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 560 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 394990003 | Family history: Ankylosing spondylitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 561 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 429712009 | Bath Ankylosing Spondylitis Disease Activity Index | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 562 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 441562009 | Bath Ankylosing Spondylitis Disease Activity Index score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 563 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 441680005 | BASFI (Bath Ankylosing Spondylitis Functional Index) score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 564 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | ankylosing spondylitis | 441930001 | BASMI (Bath Ankylosing Spondylitis Metrology Index) score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 565 | ADALIMUMAB | Ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | axial spondyloarthritis | 723116002 | Axial spondyloarthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 566 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 4927003 | Acute anterior uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 567 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 11226001 | Fuchs uveitis syndrome | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 568 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 43363007 | Posterior uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 569 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 75614007 | Panuveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 570 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 89114005 | Infectious anterior uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 571 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 95707009 | Phacotoxic uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 572 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 267619000 | Non-infectious anterior uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 573 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 312922007 | Uveitis related cystoid macular oedema | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 574 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 314029000 | Tuberculous uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 575 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 314030005 | Post-traumatic uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 576 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 314033007 | Secondary open-angle glaucoma with uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 577 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 314493000 | Postoperative uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 578 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 370506009 | Keratouveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 579 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 398155003 | Chronic anterior uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 580 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 410494003 | Phacoantigenic uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 581 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 410692006 | Anterior uveitis | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 582 | ADALIMUMAB | Non-infectious uveitis | TA460 | uveitis | 342151000119100 | Acute anterior uveitis of left eye | ADALIMUMAB | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY |
| 583 | ADALIMUMAB | Plaque psoriasis | TA146 | plaque psoriasis | 200975007 | Psoriasis vulgaris & (Chronic large plaque psoriasis) | ADALIMUMAB | DERMATOLOGY | DERMATOLOGY |
| 584 | ADALIMUMAB | Plaque psoriasis | TA146 | plaque psoriasis | 402307000 | Chronic large plaque psoriasis | ADALIMUMAB | DERMATOLOGY | DERMATOLOGY |
| 585 | ADALIMUMAB | Plaque psoriasis | TA146 | plaque psoriasis | 402310007 | Chronic stable plaque psoriasis | ADALIMUMAB | DERMATOLOGY | DERMATOLOGY |
| 586 | ADALIMUMAB | Plaque psoriasis in children and young people | TA455 | plaque psoriasis | 200975007 | Psoriasis vulgaris & (Chronic large plaque psoriasis) | ADALIMUMAB | DERMATOLOGY | DERMATOLOGY |
| 587 | ADALIMUMAB | Plaque psoriasis in children and young people | TA455 | plaque psoriasis | 402307000 | Chronic large plaque psoriasis | ADALIMUMAB | DERMATOLOGY | DERMATOLOGY |
| 588 | ADALIMUMAB | Plaque psoriasis in children and young people | TA455 | plaque psoriasis | 402310007 | Chronic stable plaque psoriasis | ADALIMUMAB | DERMATOLOGY | DERMATOLOGY |
| 589 | ADALIMUMAB | Psoriatic arthritis | TA125 | psoriatic arthritis | 156370009 | Psoriatic arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 590 | ADALIMUMAB | Psoriatic arthritis | TA199 | psoriatic arthritis | 156370009 | Psoriatic arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 591 | ADALIMUMAB | Psoriatic arthritis | TA125 | psoriatic arthritis | 239802003 | Juvenile psoriatic arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 592 | ADALIMUMAB | Psoriatic arthritis | TA199 | psoriatic arthritis | 239802003 | Juvenile psoriatic arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 593 | ADALIMUMAB | Psoriatic arthritis | TA125 | psoriatic arthritis | 239803008 | Juvenile psoriatic arthritis with psoriasis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 594 | ADALIMUMAB | Psoriatic arthritis | TA199 | psoriatic arthritis | 239803008 | Juvenile psoriatic arthritis with psoriasis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 595 | ADALIMUMAB | Psoriatic arthritis | TA125 | psoriatic arthritis | 239812005 | Psoriatic arthritis with distal interphalangeal joint involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 596 | ADALIMUMAB | Psoriatic arthritis | TA199 | psoriatic arthritis | 239812005 | Psoriatic arthritis with distal interphalangeal joint involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 597 | ADALIMUMAB | Psoriatic arthritis | TA125 | psoriatic arthritis | 430543001 | Family history of psoriasis with psoriatic arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 598 | ADALIMUMAB | Psoriatic arthritis | TA199 | psoriatic arthritis | 430543001 | Family history of psoriasis with psoriatic arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 599 | ADALIMUMAB | Psoriatic arthritis | TA125 | psoriatic arthritis | 1036471000000109 | Psoriatic Arthritis Impact of Disease 9 questionnaire score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 600 | ADALIMUMAB | Psoriatic arthritis | TA199 | psoriatic arthritis | 1036471000000109 | Psoriatic Arthritis Impact of Disease 9 questionnaire score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|DERMATOLOGY |
| 601 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 602 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 603 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 604 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 605 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 606 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 607 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 608 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 609 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 610 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 611 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 612 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 613 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 614 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 615 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 616 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 617 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 618 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 619 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 620 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 621 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 622 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 623 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 624 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 625 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 626 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 627 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 628 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 629 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 630 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 631 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 632 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 633 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 634 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 635 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 636 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 637 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 638 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 639 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 640 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 641 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 642 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 643 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 644 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 645 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 646 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 647 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 648 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 649 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 650 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 651 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 652 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 653 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 654 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 655 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 656 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 657 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 658 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 659 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 660 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 661 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 662 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 663 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 664 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 665 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 666 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 667 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 668 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 669 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 670 | ADALIMUMAB | Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 671 | ADALIMUMAB | Severe active Crohn's disease (adults) | TA187 | crohn's disease | 196578009 | Oral Crohn's disease | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY |
| 672 | ADALIMUMAB | Severe active Crohn's disease (adults) | TA187 | crohn's disease | 196578009 | Oral Crohn's disease | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY |
| 673 | ADALIMUMAB | Severe active Crohn's disease (adults) | TA187 | crohn's disease | 273364009 | Crohn's Disease Activity Index | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY |
| 674 | ADALIMUMAB | Severe active Crohn's disease (adults) | TA187 | crohn's disease | 273364009 | Crohn's Disease Activity Index | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY |
| 675 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 162930007 | On examination - ankylosing spondylitis chest deformity | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 676 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 239805001 | Juvenile ankylosing spondylitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 677 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 239810002 | Ankylosing spondylitis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 678 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 239811003 | Ankylosing spondylitis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 679 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 394990003 | Family history: Ankylosing spondylitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 680 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 429712009 | Bath Ankylosing Spondylitis Disease Activity Index | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 681 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 441562009 | Bath Ankylosing Spondylitis Disease Activity Index score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 682 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 441680005 | BASFI (Bath Ankylosing Spondylitis Functional Index) score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 683 | ADALIMUMAB | Severe ankylosing spondylitis (adults) | TA143 | ankylosing spondylitis | 441930001 | BASMI (Bath Ankylosing Spondylitis Metrology Index) score | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY |
| 684 | ADALIMUMAB | Treating juvenile idiopathic arthritis | TA373 | juvenile idiopathic arthritis | 410798004 | Oligoarticular juvenile idiopathic arthritis | ABATECEPT | RHEUMATOLOGY | RHEUMATOLOGY|PAEDIATRICS |
| 685 | ADALIMUMAB | Treating juvenile idiopathic arthritis | TA373 | juvenile idiopathic arthritis | 16044751000119106 | Juvenile idiopathic arthritis, polyarthritis | ABATECEPT | RHEUMATOLOGY | RHEUMATOLOGY|PAEDIATRICS |
| 686 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 64766004 | UC - ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 687 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 160383003 | FH: Ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 688 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 201727001 | Arthropathy in ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 689 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 275129008 | Family history of ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 690 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 275549008 | History of ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 691 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 414156000 | Exacerbation of ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 692 | ADALIMUMAB | Treatment of moderate to severe ulcerative colitis | TA262 | ulcerative colitis | 445243001 | Left sided ulcerative colitis | ADALIMUMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 693 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 64766004 | UC - ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 694 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 160383003 | FH: Ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 695 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 201727001 | Arthropathy in ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 696 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 275129008 | Family history of ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 697 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 275549008 | History of ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 698 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 414156000 | Exacerbation of ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 699 | ADALIMUMAB | moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | ulcerative colitis | 445243001 | Left sided ulcerative colitis | INFLIXIMAB | GASTROENTEROLOGY | GASTROENTEROLOGY|COLORECTAL SURGERY |
| 700 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 701 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 702 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 703 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 704 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 705 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 706 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 707 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 708 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 709 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 710 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 711 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 712 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 713 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 714 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 715 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 716 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 717 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 718 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 719 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 720 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 721 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 722 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 723 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 724 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 725 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 726 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 727 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 728 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 729 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 730 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 731 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 732 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 733 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 734 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 735 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 736 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 737 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 738 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 739 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 740 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 741 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 742 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 743 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 744 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 745 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 746 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 747 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 748 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 749 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 750 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 751 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 752 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 753 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 754 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 755 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 756 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 757 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 758 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 759 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 760 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 761 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 762 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 763 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 764 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 765 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 766 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 767 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 768 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 769 | ADALIMUMAB (1ST LINE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 770 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 771 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 772 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 773 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 774 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 775 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 776 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 777 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 778 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 779 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 780 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 781 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 782 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 783 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 784 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 785 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 786 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 787 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 788 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 789 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 790 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 791 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 792 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 793 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 794 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 795 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 796 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 797 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 798 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 799 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 800 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 801 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 802 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 803 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 804 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 805 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 806 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 807 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 808 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 809 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 810 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 811 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 812 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 813 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 814 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 815 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 816 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 817 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 818 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 819 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 820 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 821 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 822 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 823 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 824 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 825 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 826 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 827 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 828 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 829 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 830 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 831 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 832 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 833 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 834 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 835 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 836 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 837 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 838 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 839 | ADALIMUMAB (AFTER DMARD FAILURE) | Rheumatoid arthritis | TA130 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 840 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 841 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 842 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 843 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 844 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 845 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 846 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 847 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 848 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 849 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 850 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 851 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 852 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 853 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 854 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 855 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 856 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 857 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 858 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 859 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 860 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 861 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 862 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 863 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 864 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 865 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 866 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 867 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 868 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 869 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 870 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 871 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 872 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 873 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 874 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 875 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 876 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 877 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 878 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 879 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 880 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 881 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 882 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 883 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 884 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 885 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 886 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 887 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 888 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 889 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 890 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 891 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 892 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 893 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 894 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 895 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 896 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 897 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 898 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 899 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 900 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 901 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 902 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 903 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 904 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 905 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 906 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 907 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 908 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 909 | ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 910 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 911 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 912 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 913 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 914 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 915 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 916 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 917 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 918 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 919 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 920 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 921 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 922 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 923 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 924 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 925 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 926 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 927 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 928 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 929 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 930 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 931 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 932 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 933 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 934 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 935 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 936 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 937 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 938 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 939 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 940 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 941 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 942 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 943 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 944 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 945 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 946 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 947 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 948 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 949 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 950 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 951 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 952 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 953 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 954 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 955 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 956 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 957 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 958 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 959 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 960 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 961 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 962 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 963 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 964 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 965 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 966 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 967 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 968 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 969 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 970 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 971 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 972 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 973 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 974 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 975 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 976 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 977 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 978 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 979 | ADALIMUMAB MONOTHERAPY | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 980 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 981 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 982 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 983 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 984 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 985 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 986 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 987 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 988 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 989 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 990 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 991 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 992 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 993 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 994 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 995 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 996 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 997 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 998 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 999 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1000 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1001 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1002 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1003 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1004 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1005 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1006 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1007 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1008 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1009 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1010 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1011 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1012 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1013 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1014 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1015 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1016 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1017 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1018 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1019 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1020 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1021 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1022 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1023 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1024 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1025 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1026 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1027 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1028 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1029 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1030 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1031 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1032 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1033 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1034 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1035 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1036 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1037 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1038 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1039 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1040 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1041 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1042 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1043 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1044 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1045 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1046 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1047 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1048 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1049 | ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE) | Rheumatoid arthritis | TA195 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ABATACEPT | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1050 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1961000 | Chronic polyarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1051 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 28880005 | Rheumatoid arthritis with carditis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1052 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 75822003 | Acute juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1053 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 160413008 | Family history: Rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1054 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 161567008 | History of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1055 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 193180002 | Polyneuropathy in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1056 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 193250002 | Myopathy due to rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1057 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201764007 | Rheumatoid arthritis of cervical spine | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1058 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201766009 | Rheumatoid arthritis of shoulder | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1059 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201767000 | Rheumatoid arthritis of sternoclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1060 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201768005 | Rheumatoid arthritis of acromioclavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1061 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201769002 | Rheumatoid arthritis of elbow | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1062 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201771002 | Rheumatoid arthritis of wrist | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1063 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201772009 | Rheumatoid arthritis of metacarpophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1064 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201773004 | Rheumatoid arthritis of proximal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1065 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201774005 | Rheumatoid arthritis of distal interphalangeal joint of finger | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1066 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201775006 | Rheumatoid arthritis of hip | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1067 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201776007 | Rheumatoid arthritis of sacroiliac joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1068 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201777003 | Rheumatoid arthritis of knee | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1069 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201778008 | Rheumatoid arthritis of tibiofibular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1070 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201779000 | Rheumatoid arthritis of ankle | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1071 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201780002 | Rheumatoid arthritis of subtalar joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1072 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201781003 | Rheumatoid arthritis of talonavicular joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1073 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201783000 | Rheumatoid arthritis of 1st metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1074 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201784006 | Rheumatoid arthritis of lesser metatarsophalangeal joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1075 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201785007 | Rheumatoid arthritis of interphalangeal joint of toe | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1076 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201791009 | Flare of rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1077 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201796004 | Systemic onset juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1078 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 201799006 | Monoarticular juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1079 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239791005 | Seropositive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1080 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239792003 | Seronegative rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1081 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239793008 | Rheumatoid arthritis with organ / system involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1082 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 239795001 | Rheumatoid arthritis with multisystem involvement | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1083 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 275902004 | Rheumatoid arthritis monitoring | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1084 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287006005 | Rheumatoid arthritis of multiple joints | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1085 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287007001 | Rheumatoid arthritis of hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1086 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 287008006 | Rheumatoid arthritis of ankle and/or foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1087 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 308143008 | Seropositive erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1088 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 398640008 | Rheumatoid arthritis with pneumoconiosis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1089 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 399923009 | Rheumatoid arthritis with arteritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1090 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 400054000 | Rheumatoid arthritis with vasculitis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1091 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 410502007 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1092 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 410795001 | Juvenile rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1093 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 429192004 | Rheumatoid arthritis of foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1094 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 443728000 | Disease activity score 28 joint in rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1095 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 735599007 | Rheumatoid arthritis with erosion of joint | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1096 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1162303002 | Seronegative erosive rheumatoid arthritis | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1097 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 143441000000104 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1098 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 143441000119108 | Rheumatoid arthritis in remission | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1099 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805941000000105 | Exception reporting - rheumatoid arthritis quality indicators | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1100 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805961000000106 | Excepted from rheumatoid arthritis quality indicators - patient unsuitable | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1101 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 805981000000102 | Excepted from rheumatoid arthritis quality indicators - informed dissent | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1102 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 847261000000104 | Rheumatoid arthritis annual review | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1103 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882321000000105 | Rheumatoid arthritis monitoring invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1104 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882401000000106 | Rheumatoid arthritis monitoring invitation first letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1105 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882421000000102 | Rheumatoid arthritis monitoring invitation second letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1106 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882441000000109 | Rheumatoid arthritis monitoring invitation third letter | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1107 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882461000000105 | Rheumatoid arthritis monitoring verbal invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1108 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 882481000000101 | Rheumatoid arthritis monitoring telephone invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1109 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1010071000000108 | Rheumatoid arthritis particle agglutination test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1110 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1016811000000108 | Rheumatoid arthritis screening test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1111 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1029271000000101 | Rheumatoid arthritis latex test | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1112 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1066991000000109 | Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1113 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067001000000103 | Rheumatoid arthritis monitoring SMS (short message service) text message first invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1114 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067011000000101 | Rheumatoid arthritis monitoring SMS (short message service) text message second invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1115 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1067021000000107 | Rheumatoid arthritis monitoring SMS (short message service) text message third invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1116 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1073781000119104 | Rheumatoid arthritis of right foot | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1117 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1073791000119101 | Rheumatoid arthritis of right hand | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1118 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1083081000000100 | Rheumatoid arthritis monitoring invitation email | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1119 | ADALIMUMAB WITH METHOTREXATE | Moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | rheumatoid arthritis | 1110961000000108 | QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation | ADALIMUMAB | RHEUMATOLOGY | RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE |
| 1120 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 16584000 | Administration of vaccine product containing only Hepatitis B virus antigen | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1121 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 17627009 | Hepatitis B e antigen Ab | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1122 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 22290004 | Hepatitis B virus surface antigen | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1123 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 47758006 | Hepatitis B surface antigen level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1124 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 61977001 | Chronic viral hepatitis B | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1125 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 76795007 | Acute hepatitis B | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1126 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 81665004 | Hepatitis B virus | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1127 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 82409003 | Hepatitis B core antigen Ab | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1128 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 82645009 | Hepatitis B virus surface antigen Ab | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1129 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 116800003 | Hepatitis B Virus immune globulin administration | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1130 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 122450004 | Hepatitis B virus antibody | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1131 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 161638000 | Hepatitis B Occupational risk | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1132 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 165806002 | Hepatitis B surface antigen positive | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1133 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 165807006 | Hepatitis Be antigen present | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1134 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 165808001 | Hepatitis B non-immune | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1135 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170370000 | First hepatitis B immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1136 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170371001 | Administration of second dose of hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1137 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170372008 | Third hepatitis B immunisation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1138 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170373003 | Hepatitis B booster vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1139 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170374009 | Fourth hepatitis B immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1140 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170375005 | Administration of fifth dose of hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1141 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170436000 | Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1142 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 170542003 | Requires course of hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1143 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 171122006 | Hepatitis B screening | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1144 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 171123001 | Hepatitis B screening required | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1145 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 186626002 | Acute hepatitis B with delta-agent (coinfection) without hepatic coma | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1146 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 192723002 | Post hepatitis B vaccination encephalitis | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1147 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 235871004 | Hepatitis B carrier | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1148 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 268504008 | Anti-hepatitis B immunoglobulin given | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1149 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 271511000 | Hepatitis B immune | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1150 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 278969009 | Hepatitis B status | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1151 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 293110008 | Adverse reaction to component of vaccine product containing Hepatitis B virus antigen | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1152 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 294637001 | Hepatitis B immunoglobulin allergy | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1153 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 294646007 | Hepatitis B vaccine allergy | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1154 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 303233001 | Antigen of Hepatitis B virus | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1155 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 313234004 | Hepatitis B antibody present | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1156 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 406010001 | Hepatitis B surface antigen not detected | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1157 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 408778004 | Hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1158 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 416923003 | Sixth hepatitis B immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1159 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 425569004 | Hepatitis B immunization recommended | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1160 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 426519003 | History of two doses hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1161 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 426980004 | History of one dose of hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1162 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 427390007 | History of hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1163 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 429203008 | History of three hepatitis B vaccinations | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1164 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 429721005 | History of hepatitis B | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1165 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 698604002 | Hepatitis B outbreak education | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1166 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 699037006 | Hepatitis B vaccination contraindicated | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1167 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 707287001 | Hepatitis B vaccination not indicated | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1168 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 736687002 | Hepatitis B core antibody detected | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1169 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 736693005 | Hepatitis B core antibody negative | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1170 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 736699009 | Requires hepatitis B booster | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1171 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 770608009 | Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1172 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 770616000 | First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1173 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 770617009 | Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1174 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 770618004 | Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1175 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1162640003 | Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1176 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 198041000000109 | Hepatitis B vaccination refused | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1177 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 201591000000101 | Advice on hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1178 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 202271000000108 | Hepatitis B screening declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1179 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 204681000000104 | Hepatitis B screening counselling | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1180 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 221021000000103 | Hepatitis B treatment drugs Band 1 | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1181 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 356121000000100 | Hepatitis B screening positive | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1182 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 362851000000109 | Hepatitis B screening negative | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1183 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 835791000000107 | Hepatitis B vaccination invitation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1184 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 835811000000108 | Hepatitis B vaccination invitation first letter | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1185 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 835831000000100 | Hepatitis B vaccination invitation second letter | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1186 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 835851000000107 | Hepatitis B vaccination invitation third letter | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1187 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 835871000000103 | Hepatitis B vaccination verbal invitation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1188 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 839711000000101 | Hepatitis B vaccination not offered | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1189 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 846421000000105 | Hepatitis B screening not offered | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1190 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 865061000000108 | First hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1191 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 865081000000104 | Second hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1192 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 865101000000105 | Third hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1193 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 865121000000101 | Fourth hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1194 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 991971000000109 | Hepatitis B immunity test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1195 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 991981000000106 | Hepatitis B core antigen test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1196 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 991991000000108 | Hepatitis B e antigen test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1197 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 995941000000101 | Anti HBc (hepatitis B core) IgG level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1198 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1008441000000106 | Hepatitis B deoxyribonucleic acid detection assay | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1199 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1008791000000106 | HBsAg (hepatitis B surface antigen) antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1200 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1009271000000109 | Hepatitis B screening test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1201 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1014201000000102 | Hepatitis B surface antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1202 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1014211000000100 | Hepatitis B surface antigen level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1203 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1014231000000108 | Hepatitis B core antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1204 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1014241000000104 | Hepatitis B e antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1205 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1028341000000105 | Hepatitis B antigen screening | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1206 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1037211000000101 | First hepatitis B vaccination given by other healthcare provider | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1207 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1037231000000109 | Second hepatitis B vaccination given by other healthcare provider | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1208 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1060591000000103 | Hepatitis B resolved | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1209 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1082431000000104 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1210 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1082441000000108 | First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1211 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1082451000000106 | Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1212 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1082461000000109 | Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1213 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1082521000000100 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1214 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1083421000000107 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1215 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1086431000000100 | First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1216 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1086441000000109 | Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1217 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1086451000000107 | Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1218 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1091701000000105 | At risk of hepatitis B infection | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1219 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 1107691000000105 | Hepatitis B screening offered | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1220 | ADEFOVIR DIPIVOXIL | Hepatitis B (chronic) | TA096 | hepatitis b | 2427211000000109 | Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1221 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 16584000 | Administration of vaccine product containing only Hepatitis B virus antigen | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1222 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 17627009 | Hepatitis B e antigen Ab | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1223 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 22290004 | Hepatitis B virus surface antigen | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1224 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 47758006 | Hepatitis B surface antigen level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1225 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 61977001 | Chronic viral hepatitis B | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1226 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 76795007 | Acute hepatitis B | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1227 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 81665004 | Hepatitis B virus | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1228 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 82409003 | Hepatitis B core antigen Ab | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1229 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 82645009 | Hepatitis B virus surface antigen Ab | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1230 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 116800003 | Hepatitis B Virus immune globulin administration | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1231 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 122450004 | Hepatitis B virus antibody | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1232 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 161638000 | Hepatitis B Occupational risk | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1233 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 165806002 | Hepatitis B surface antigen positive | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1234 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 165807006 | Hepatitis Be antigen present | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1235 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 165808001 | Hepatitis B non-immune | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1236 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170370000 | First hepatitis B immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1237 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170371001 | Administration of second dose of hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1238 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170372008 | Third hepatitis B immunisation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1239 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170373003 | Hepatitis B booster vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1240 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170374009 | Fourth hepatitis B immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1241 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170375005 | Administration of fifth dose of hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1242 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170436000 | Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1243 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 170542003 | Requires course of hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1244 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 171122006 | Hepatitis B screening | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1245 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 171123001 | Hepatitis B screening required | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1246 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 186626002 | Acute hepatitis B with delta-agent (coinfection) without hepatic coma | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1247 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 192723002 | Post hepatitis B vaccination encephalitis | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1248 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 235871004 | Hepatitis B carrier | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1249 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 268504008 | Anti-hepatitis B immunoglobulin given | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1250 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 271511000 | Hepatitis B immune | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1251 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 278969009 | Hepatitis B status | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1252 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 293110008 | Adverse reaction to component of vaccine product containing Hepatitis B virus antigen | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1253 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 294637001 | Hepatitis B immunoglobulin allergy | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1254 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 294646007 | Hepatitis B vaccine allergy | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1255 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 303233001 | Antigen of Hepatitis B virus | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1256 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 313234004 | Hepatitis B antibody present | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1257 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 406010001 | Hepatitis B surface antigen not detected | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1258 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 408778004 | Hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1259 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 416923003 | Sixth hepatitis B immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1260 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 425569004 | Hepatitis B immunization recommended | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1261 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 426519003 | History of two doses hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1262 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 426980004 | History of one dose of hepatitis B vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1263 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 427390007 | History of hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1264 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 429203008 | History of three hepatitis B vaccinations | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1265 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 429721005 | History of hepatitis B | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1266 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 698604002 | Hepatitis B outbreak education | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1267 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 699037006 | Hepatitis B vaccination contraindicated | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1268 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 707287001 | Hepatitis B vaccination not indicated | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1269 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 736687002 | Hepatitis B core antibody detected | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1270 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 736693005 | Hepatitis B core antibody negative | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1271 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 736699009 | Requires hepatitis B booster | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1272 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 770608009 | Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1273 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 770616000 | First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1274 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 770617009 | Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1275 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 770618004 | Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1276 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1162640003 | Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1277 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 198041000000109 | Hepatitis B vaccination refused | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1278 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 201591000000101 | Advice on hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1279 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 202271000000108 | Hepatitis B screening declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1280 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 204681000000104 | Hepatitis B screening counselling | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1281 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 221021000000103 | Hepatitis B treatment drugs Band 1 | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1282 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 356121000000100 | Hepatitis B screening positive | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1283 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 362851000000109 | Hepatitis B screening negative | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1284 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 835791000000107 | Hepatitis B vaccination invitation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1285 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 835811000000108 | Hepatitis B vaccination invitation first letter | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1286 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 835831000000100 | Hepatitis B vaccination invitation second letter | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1287 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 835851000000107 | Hepatitis B vaccination invitation third letter | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1288 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 835871000000103 | Hepatitis B vaccination verbal invitation | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1289 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 839711000000101 | Hepatitis B vaccination not offered | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1290 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 846421000000105 | Hepatitis B screening not offered | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1291 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 865061000000108 | First hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1292 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 865081000000104 | Second hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1293 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 865101000000105 | Third hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1294 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 865121000000101 | Fourth hepatitis B junior vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1295 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 991971000000109 | Hepatitis B immunity test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1296 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 991981000000106 | Hepatitis B core antigen test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1297 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 991991000000108 | Hepatitis B e antigen test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1298 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 995941000000101 | Anti HBc (hepatitis B core) IgG level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1299 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1008441000000106 | Hepatitis B deoxyribonucleic acid detection assay | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1300 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1008791000000106 | HBsAg (hepatitis B surface antigen) antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1301 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1009271000000109 | Hepatitis B screening test | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1302 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1014201000000102 | Hepatitis B surface antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1303 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1014211000000100 | Hepatitis B surface antigen level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1304 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1014231000000108 | Hepatitis B core antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1305 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1014241000000104 | Hepatitis B e antibody level | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1306 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1028341000000105 | Hepatitis B antigen screening | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1307 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1037211000000101 | First hepatitis B vaccination given by other healthcare provider | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1308 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1037231000000109 | Second hepatitis B vaccination given by other healthcare provider | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1309 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1060591000000103 | Hepatitis B resolved | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1310 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1082431000000104 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1311 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1082441000000108 | First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1312 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1082451000000106 | Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1313 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1082461000000109 | Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1314 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1082521000000100 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1315 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1083421000000107 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1316 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1086431000000100 | First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1317 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1086441000000109 | Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1318 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1086451000000107 | Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1319 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1091701000000105 | At risk of hepatitis B infection | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1320 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 1107691000000105 | Hepatitis B screening offered | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1321 | ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE | Hepatitis B (chronic) | TA096 | hepatitis b | 2427211000000109 | Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination | ADEFOVIR | GASTROENTEROLOGY | GASTROENTEROLOGY|INFECTIOUS DISEASES |
| 1322 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 162573006 | Suspected lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1323 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 254637007 | Non-small cell lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1324 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 275981009 | Lung cancer screening | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1325 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 429011007 | Family history of lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1326 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 723301009 | Squamous non-small cell lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1327 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 1259727001 | Primary non-small cell lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1328 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 1259754003 | Primary squamous NSCLC (non-small cell lung cancer) | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1329 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 276491000000101 | Fast track referral for suspected lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1330 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 382681000000102 | Seen in fast track suspected lung cancer clinic | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1331 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 848881000000108 | QCancer lung cancer risk | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1332 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 877691000000107 | No FH of lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1333 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 1771781000000107 | Did not attend lung cancer screening | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1334 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 1792021000000109 | PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1335 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 1792031000000106 | Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1336 | AFATINIB | Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy | TA444 | non-small-cell lung cancer | 1792041000000102 | Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1337 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 162573006 | Suspected lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1338 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 254637007 | Non-small cell lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1339 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 275981009 | Lung cancer screening | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1340 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 429011007 | Family history of lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1341 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 723301009 | Squamous non-small cell lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1342 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 1259727001 | Primary non-small cell lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1343 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 1259754003 | Primary squamous NSCLC (non-small cell lung cancer) | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1344 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 276491000000101 | Fast track referral for suspected lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1345 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 382681000000102 | Seen in fast track suspected lung cancer clinic | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1346 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 848881000000108 | QCancer lung cancer risk | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1347 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 877691000000107 | No FH of lung cancer | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1348 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 1771781000000107 | Did not attend lung cancer screening | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1349 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 1792021000000109 | PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1350 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 1792031000000106 | Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1351 | AFATINIB | Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | non-small-cell lung cancer | 1792041000000102 | Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers | AFATINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1352 | AFLIBERCEPT | Choroidal neovascularisation | TA486 | choroidal neovascularisation | 733124000 | Myopic choroidal neovascularisation | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1353 | AFLIBERCEPT | Choroidal neovascularisation | TA486 | choroidal neovascularisation | 380621000000102 | Subfoveal choroidal neovascularisation drugs Band 1 | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1354 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 37231002 | Macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1355 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | retinal vein occlusion | 232038007 | Central retinal vein occlusion with neovascularization | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1356 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 232039004 | Central retinal vein occlusion with macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1357 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | retinal vein occlusion | 232042005 | Macular edema due to juvenile central retinal vein occlusion | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1358 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 232045007 | Macular oedema due to hemispheric retinal vein occlusion | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1359 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | retinal vein occlusion | 232045007 | Macular oedema due to hemispheric retinal vein occlusion | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1360 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 312911008 | CSME - clinically significant macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1361 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 312912001 | Macular oedema due to diabetes mellitus | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1362 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 312920004 | Postoperative cystoid macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1363 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 312921000 | Autosomal dominant cystoid macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1364 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 312922007 | Uveitis related cystoid macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1365 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 769218003 | Macular oedema of left eye due to diabetes mellitus | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1366 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 769221001 | Clinically significant macular oedema of right eye due to diabetes mellitus | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1367 | AFLIBERCEPT | Treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | macular oedema | 895021000000102 | Macular oedema drugs Band 1 | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1368 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 37231002 | Macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1369 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | retinal vein occlusion | 232038007 | Central retinal vein occlusion with neovascularization | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1370 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 232039004 | Central retinal vein occlusion with macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1371 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | retinal vein occlusion | 232042005 | Macular edema due to juvenile central retinal vein occlusion | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1372 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 232045007 | Macular oedema due to hemispheric retinal vein occlusion | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1373 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | retinal vein occlusion | 232045007 | Macular oedema due to hemispheric retinal vein occlusion | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1374 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 312911008 | CSME - clinically significant macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1375 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 312912001 | Macular oedema due to diabetes mellitus | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1376 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 312920004 | Postoperative cystoid macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1377 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 312921000 | Autosomal dominant cystoid macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1378 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 312922007 | Uveitis related cystoid macular oedema | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1379 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 769218003 | Macular oedema of left eye due to diabetes mellitus | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1380 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 769221001 | Clinically significant macular oedema of right eye due to diabetes mellitus | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1381 | AFLIBERCEPT SOLUTION FOR INJECTION | Visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | macular oedema | 895021000000102 | Macular oedema drugs Band 1 | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1382 | AFLIBERCEPT SOLUTION FOR INJECTION | Wet age‑related macular degeneration | TA294 | macular degeneration | 70099003 | Familial juvenile macular degeneration syndrome | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1383 | AFLIBERCEPT SOLUTION FOR INJECTION | Wet age‑related macular degeneration | TA294 | macular degeneration | 193384000 | Senile macular degeneration | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1384 | AFLIBERCEPT SOLUTION FOR INJECTION | Wet age‑related macular degeneration | TA294 | macular degeneration | 267718000 | Age-related macular degeneration | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1385 | AFLIBERCEPT SOLUTION FOR INJECTION | Wet age‑related macular degeneration | TA294 | macular degeneration | 312898002 | Myopic macular degeneration | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1386 | AFLIBERCEPT SOLUTION FOR INJECTION | Wet age‑related macular degeneration | TA294 | macular degeneration | 314427006 | Drusen plus pigment change stage macular degeneration | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1387 | AFLIBERCEPT SOLUTION FOR INJECTION | Wet age‑related macular degeneration | TA294 | macular degeneration | 1296526000 | Disciform macular degeneration | AFLIBERCEPT | OPHTHALMOLOGY | OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY |
| 1388 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 191610000 | Recurrent major depressive episodes, mild | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1389 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 191611001 | Recurrent major depressive episodes, moderate | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1390 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 191613003 | Recurrent major depressive episodes, severe, with psychosis | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1391 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 268621008 | Recurrent major depressive episodes | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1392 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 755331000000108 | Recurrent major depressive episodes, severe, with psychosis, psychosis in remission | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1393 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 764611000000100 | Recurrent major depressive episodes, severe | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1394 | AGOMELATINE | Major depressive episodes | TA231 | major depressive episodes | 764691000000109 | Recurrent major depressive episodes, in partial remission | AGOMELATINE | MENTAL HEALTH | MENTAL HEALTH |
| 1395 | ALCLOMETASONE DIPROPIONATE | Atopic dermatitis (eczema) | TA081 | atopic dermatitis | 238542007 | Inverse pattern atopic dermatitis | ALCLOMETASONE | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 1396 | ALCLOMETASONE DIPROPIONATE | Atopic dermatitis (eczema) | TA081 | atopic dermatitis | 238543002 | Discoid atopic dermatitis | ALCLOMETASONE | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 1397 | ALCLOMETASONE DIPROPIONATE | Atopic dermatitis (eczema) | TA081 | atopic dermatitis | 238544008 | Erythrodermic atopic dermatitis | ALCLOMETASONE | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 1398 | ALCLOMETASONE DIPROPIONATE | Atopic dermatitis (eczema) | TA081 | atopic dermatitis | 238545009 | Follicular atopic dermatitis | ALCLOMETASONE | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 1399 | ALCLOMETASONE DIPROPIONATE | Atopic dermatitis (eczema) | TA081 | atopic dermatitis | 238546005 | Pruriginous atopic dermatitis | ALCLOMETASONE | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 1400 | ALCLOMETASONE DIPROPIONATE | Atopic dermatitis (eczema) | TA081 | atopic dermatitis | 584621000000108 | Atopic dermatitis NOS | ALCLOMETASONE | DERMATOLOGY | DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY |
| 1401 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 162573006 | Suspected lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1402 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 254637007 | Non-small cell lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1403 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 275981009 | Lung cancer screening | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1404 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 429011007 | Family history of lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1405 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 723301009 | Squamous non-small cell lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1406 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 1259727001 | Primary non-small cell lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1407 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 1259754003 | Primary squamous NSCLC (non-small cell lung cancer) | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1408 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 276491000000101 | Fast track referral for suspected lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1409 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 382681000000102 | Seen in fast track suspected lung cancer clinic | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1410 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 848881000000108 | QCancer lung cancer risk | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1411 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 877691000000107 | No FH of lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1412 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 1771781000000107 | Did not attend lung cancer screening | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1413 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 1792021000000109 | PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1414 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 1792031000000106 | Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1415 | ALECTINIB | Non-small-cell lung cancer | TA536 | non-small-cell lung cancer | 1792041000000102 | Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1416 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 162573006 | Suspected lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1417 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 254637007 | Non-small cell lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1418 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 275981009 | Lung cancer screening | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1419 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 429011007 | Family history of lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1420 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 723301009 | Squamous non-small cell lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1421 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 1259727001 | Primary non-small cell lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1422 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 1259754003 | Primary squamous NSCLC (non-small cell lung cancer) | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1423 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 276491000000101 | Fast track referral for suspected lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1424 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 382681000000102 | Seen in fast track suspected lung cancer clinic | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1425 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 848881000000108 | QCancer lung cancer risk | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1426 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 877691000000107 | No FH of lung cancer | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1427 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 1771781000000107 | Did not attend lung cancer screening | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1428 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 1792021000000109 | PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1429 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 1792031000000106 | Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1430 | ALECTINIB | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA438 | non-small-cell lung cancer | 1792041000000102 | Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers | ALECTINIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY |
| 1431 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 24700007 | Multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1432 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 160337009 | Family history of multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1433 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 192926004 | Brain stem multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1434 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 192927008 | Multiple sclerosis of the spinal cord | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1435 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 192928003 | Generalised multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1436 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 192929006 | Exacerbation of multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1437 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 230372003 | Acute relapsing multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1438 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 230373008 | Chronic progressive multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1439 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 230374002 | Remittent-progressive multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1440 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 425500002 | Secondary progressive multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1441 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 426373005 | Relapsing remitting multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1442 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 428700003 | Primary progressive multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1443 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 438511000 | Benign multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1444 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 698626001 | Dementia associated with multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1445 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 700409000 | Suspected multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1446 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 724778008 | Progressive relapsing multiple sclerosis | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1447 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 166411000000100 | Specialised services for patients with multiple sclerosis enhanced services administration | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1448 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 198491000000106 | Multiple sclerosis review | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1449 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 205631000000104 | Multiple sclerosis multidisciplinary review | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1450 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 367591000000101 | Management of multiple sclerosis in early disease phase | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1451 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 367621000000103 | Management of multiple sclerosis in stable disability phase | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1452 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 367651000000108 | Management of multiple sclerosis in progressive disability phase | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1453 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 515931000000104 | Multiple sclerosis review declined | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1454 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 758981000000100 | Multiple sclerosis monitoring administration | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1455 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 759091000000105 | Multiple sclerosis monitoring second letter | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1456 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 759131000000108 | Multiple sclerosis monitoring telephone invitation | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1457 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 785851000000104 | Referral to community multiple sclerosis team | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1458 | ALEMTUZUMAB | Relapsing-remitting multiple sclerosis | TA312 | multiple sclerosis | 811881000000109 | Multiple sclerosis care plan agreed | ALEMTUZUMAB | NEUROLOGY | NEUROLOGY|REHABILITATION |
| 1459 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 14651005 | Drug-induced osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1460 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 18040001 | Age-related osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1461 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 64859006 | Osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1462 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 102447009 | Postmenopausal osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1463 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 160313009 | Family history of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1464 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203429007 | Idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1465 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203433000 | Postoophorectomy osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1466 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203435007 | Localized osteoporosis - Lequesne | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1467 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203437004 | Osteoporosis in endocrine disorders | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1468 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203438009 | Osteoporosis of spine | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1469 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203444008 | Osteoporotic fracture due to postoophorectomy osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1470 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203445009 | Osteoporosis of disuse with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1471 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203447001 | Drug-induced osteoporosis with osteoporotic fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1472 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203448006 | Idiopathic osteoporosis with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1473 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 203453001 | Postmenopausal osteoporosis with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1474 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240155001 | Adult idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1475 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240156000 | Juvenile idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1476 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240157009 | Secondary generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1477 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240158004 | Regional migrating osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1478 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240159007 | Transient osteoporosis of hip | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1479 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240160002 | Transient osteoporosis of hip in pregnancy | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1480 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 240162005 | Secondary localized osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1481 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 268028001 | Localised disuse osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1482 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 276661002 | Primary osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1483 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 281387004 | Regional osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1484 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 300004007 | Screening for osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1485 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 309745002 | Osteoporosis localized to spine | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1486 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 310251007 | No family history: Osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1487 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 313423004 | At increased risk of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1488 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 390833005 | Osteoporosis caused by corticosteroid | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1489 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391003008 | Osteoporosis monitoring administration | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1490 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391004002 | Attends osteoporosis monitoring | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1491 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391006000 | Osteoporosis monitoring default | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1492 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391007009 | Osteoporosis monitoring first letter | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1493 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391008004 | Osteoporosis monitoring second letter | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1494 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391011003 | Osteoporosis monitoring telephone invitation | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1495 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391012005 | Osteoporosis monitoring deleted | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1496 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391013000 | Osteoporosis monitoring check done | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1497 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391014006 | Osteoporosis risk assessment done | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1498 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391015007 | Osteoporosis risk assessment declined | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1499 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391016008 | Osteoporosis risk assessment defaulted | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1500 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391017004 | Osteoporosis monitoring | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1501 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391018009 | Initial osteoporosis assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1502 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391019001 | Follow-up osteoporosis assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1503 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391020007 | Osteoporosis treatment started | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1504 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391021006 | Osteoporosis treatment stopped | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1505 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391022004 | Osteoporosis treatment changed | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1506 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391023009 | Osteoporosis - no treatment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1507 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391024003 | Osteoporosis - dietary advice | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1508 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391025002 | Osteoporosis - dietary assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1509 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391026001 | Osteoporosis - exercise advice | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1510 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391027005 | Osteoporosis - falls prevention | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1511 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391028000 | Osteoporosis - treatment response | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1512 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391033001 | Refer to osteoporosis specialist | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1513 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391037000 | Seen in osteoporosis clinic | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1514 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391060008 | Dual energy X-ray absorptiometry of bone of forearm result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1515 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391065003 | Dual energy X-ray absorptiometry of calcaneum result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1516 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391070005 | Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1517 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 391075000 | Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1518 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 394936006 | Health education - osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1519 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 412717001 | Referral to osteoporosis clinic | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1520 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 440100002 | Dual energy X-ray absorptiometry of neck of femur result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1521 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 473120007 | History of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1522 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 739301006 | Osteoporosis co-occurrent and due to multiple myeloma | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1523 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 763322002 | Osteoporosis monitoring refused | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1524 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 278781000000105 | Osteoporosis treatment not indicated | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1525 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 505141000000108 | Osteoporosis enhanced services administration | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1526 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 505171000000102 | Bone sparing drug treatment offered for osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1527 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 711141000000109 | Osteoporosis medication prophylaxis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1528 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 711341000000106 | Osteoporosis resolved | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1529 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 753711000000102 | Exception reporting - osteoporosis quality indicators | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1530 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 753791000000106 | Excepted from osteoporosis quality indicators - patient unsuitable | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1531 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 753831000000104 | Excepted from osteoporosis quality indicators - informed dissent | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1532 | ALENDRONATE | Fragility fractures in postmenopausal women with osteoporosis (secondary prevention) | TA161 | osteoporosis | 965871000000101 | Osteoporosis medication compliance review | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1533 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 14651005 | Drug-induced osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1534 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 18040001 | Age-related osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1535 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 64859006 | Osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1536 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 102447009 | Postmenopausal osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1537 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 160313009 | Family history of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1538 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203429007 | Idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1539 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203433000 | Postoophorectomy osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1540 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203435007 | Localized osteoporosis - Lequesne | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1541 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203437004 | Osteoporosis in endocrine disorders | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1542 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203438009 | Osteoporosis of spine | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1543 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203444008 | Osteoporotic fracture due to postoophorectomy osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1544 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203445009 | Osteoporosis of disuse with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1545 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203447001 | Drug-induced osteoporosis with osteoporotic fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1546 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203448006 | Idiopathic osteoporosis with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1547 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 203453001 | Postmenopausal osteoporosis with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1548 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240155001 | Adult idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1549 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240156000 | Juvenile idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1550 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240157009 | Secondary generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1551 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240158004 | Regional migrating osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1552 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240159007 | Transient osteoporosis of hip | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1553 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240160002 | Transient osteoporosis of hip in pregnancy | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1554 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 240162005 | Secondary localized osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1555 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 268028001 | Localised disuse osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1556 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 276661002 | Primary osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1557 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 281387004 | Regional osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1558 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 300004007 | Screening for osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1559 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 309745002 | Osteoporosis localized to spine | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1560 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 310251007 | No family history: Osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1561 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 313423004 | At increased risk of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1562 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 390833005 | Osteoporosis caused by corticosteroid | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1563 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391003008 | Osteoporosis monitoring administration | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1564 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391004002 | Attends osteoporosis monitoring | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1565 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391006000 | Osteoporosis monitoring default | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1566 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391007009 | Osteoporosis monitoring first letter | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1567 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391008004 | Osteoporosis monitoring second letter | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1568 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391011003 | Osteoporosis monitoring telephone invitation | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1569 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391012005 | Osteoporosis monitoring deleted | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1570 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391013000 | Osteoporosis monitoring check done | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1571 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391014006 | Osteoporosis risk assessment done | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1572 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391015007 | Osteoporosis risk assessment declined | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1573 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391016008 | Osteoporosis risk assessment defaulted | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1574 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391017004 | Osteoporosis monitoring | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1575 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391018009 | Initial osteoporosis assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1576 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391019001 | Follow-up osteoporosis assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1577 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391020007 | Osteoporosis treatment started | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1578 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391021006 | Osteoporosis treatment stopped | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1579 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391022004 | Osteoporosis treatment changed | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1580 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391023009 | Osteoporosis - no treatment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1581 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391024003 | Osteoporosis - dietary advice | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1582 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391025002 | Osteoporosis - dietary assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1583 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391026001 | Osteoporosis - exercise advice | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1584 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391027005 | Osteoporosis - falls prevention | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1585 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391028000 | Osteoporosis - treatment response | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1586 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391033001 | Refer to osteoporosis specialist | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1587 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391037000 | Seen in osteoporosis clinic | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1588 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391060008 | Dual energy X-ray absorptiometry of bone of forearm result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1589 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391065003 | Dual energy X-ray absorptiometry of calcaneum result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1590 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391070005 | Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1591 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 391075000 | Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1592 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 394936006 | Health education - osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1593 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 412717001 | Referral to osteoporosis clinic | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1594 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 440100002 | Dual energy X-ray absorptiometry of neck of femur result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1595 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 473120007 | History of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1596 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 739301006 | Osteoporosis co-occurrent and due to multiple myeloma | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1597 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 763322002 | Osteoporosis monitoring refused | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1598 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 278781000000105 | Osteoporosis treatment not indicated | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1599 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 505141000000108 | Osteoporosis enhanced services administration | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1600 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 505171000000102 | Bone sparing drug treatment offered for osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1601 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 711141000000109 | Osteoporosis medication prophylaxis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1602 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 711341000000106 | Osteoporosis resolved | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1603 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 753711000000102 | Exception reporting - osteoporosis quality indicators | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1604 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 753791000000106 | Excepted from osteoporosis quality indicators - patient unsuitable | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1605 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 753831000000104 | Excepted from osteoporosis quality indicators - informed dissent | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1606 | ALENDRONATE | Osteoporosis - secondary prevention | TA087 | osteoporosis | 965871000000101 | Osteoporosis medication compliance review | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1607 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 14651005 | Drug-induced osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1608 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 18040001 | Age-related osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1609 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 64859006 | Osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1610 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 102447009 | Postmenopausal osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1611 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 160313009 | Family history of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1612 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203429007 | Idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1613 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203433000 | Postoophorectomy osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1614 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203435007 | Localized osteoporosis - Lequesne | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1615 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203437004 | Osteoporosis in endocrine disorders | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1616 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203438009 | Osteoporosis of spine | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1617 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203444008 | Osteoporotic fracture due to postoophorectomy osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1618 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203445009 | Osteoporosis of disuse with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1619 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203447001 | Drug-induced osteoporosis with osteoporotic fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1620 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203448006 | Idiopathic osteoporosis with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1621 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 203453001 | Postmenopausal osteoporosis with pathological fracture | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1622 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240155001 | Adult idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1623 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240156000 | Juvenile idiopathic generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1624 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240157009 | Secondary generalised osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1625 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240158004 | Regional migrating osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1626 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240159007 | Transient osteoporosis of hip | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1627 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240160002 | Transient osteoporosis of hip in pregnancy | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1628 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 240162005 | Secondary localized osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1629 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 268028001 | Localised disuse osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1630 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 276661002 | Primary osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1631 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 281387004 | Regional osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1632 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 300004007 | Screening for osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1633 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 309745002 | Osteoporosis localized to spine | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1634 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 310251007 | No family history: Osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1635 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 313423004 | At increased risk of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1636 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 390833005 | Osteoporosis caused by corticosteroid | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1637 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391003008 | Osteoporosis monitoring administration | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1638 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391004002 | Attends osteoporosis monitoring | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1639 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391006000 | Osteoporosis monitoring default | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1640 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391007009 | Osteoporosis monitoring first letter | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1641 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391008004 | Osteoporosis monitoring second letter | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1642 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391011003 | Osteoporosis monitoring telephone invitation | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1643 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391012005 | Osteoporosis monitoring deleted | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1644 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391013000 | Osteoporosis monitoring check done | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1645 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391014006 | Osteoporosis risk assessment done | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1646 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391015007 | Osteoporosis risk assessment declined | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1647 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391016008 | Osteoporosis risk assessment defaulted | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1648 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391017004 | Osteoporosis monitoring | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1649 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391018009 | Initial osteoporosis assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1650 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391019001 | Follow-up osteoporosis assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1651 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391020007 | Osteoporosis treatment started | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1652 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391021006 | Osteoporosis treatment stopped | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1653 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391022004 | Osteoporosis treatment changed | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1654 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391023009 | Osteoporosis - no treatment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1655 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391024003 | Osteoporosis - dietary advice | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1656 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391025002 | Osteoporosis - dietary assessment | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1657 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391026001 | Osteoporosis - exercise advice | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1658 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391027005 | Osteoporosis - falls prevention | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1659 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391028000 | Osteoporosis - treatment response | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1660 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391033001 | Refer to osteoporosis specialist | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1661 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391037000 | Seen in osteoporosis clinic | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1662 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391060008 | Dual energy X-ray absorptiometry of bone of forearm result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1663 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391065003 | Dual energy X-ray absorptiometry of calcaneum result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1664 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391070005 | Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1665 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 391075000 | Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1666 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 394936006 | Health education - osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1667 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 412717001 | Referral to osteoporosis clinic | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1668 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 440100002 | Dual energy X-ray absorptiometry of neck of femur result osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1669 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 473120007 | History of osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1670 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 739301006 | Osteoporosis co-occurrent and due to multiple myeloma | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1671 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 763322002 | Osteoporosis monitoring refused | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1672 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 278781000000105 | Osteoporosis treatment not indicated | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1673 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 505141000000108 | Osteoporosis enhanced services administration | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1674 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 505171000000102 | Bone sparing drug treatment offered for osteoporosis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1675 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 711141000000109 | Osteoporosis medication prophylaxis | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1676 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 711341000000106 | Osteoporosis resolved | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1677 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 753711000000102 | Exception reporting - osteoporosis quality indicators | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1678 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 753791000000106 | Excepted from osteoporosis quality indicators - patient unsuitable | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1679 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 753831000000104 | Excepted from osteoporosis quality indicators - informed dissent | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1680 | ALENDRONATE | Primary prevention of fragility fractures in postmenopausal women with osteoporosis | TA160 | osteoporosis | 965871000000101 | Osteoporosis medication compliance review | ALENDRONATE | RHEUMATOLOGY | RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE |
| 1681 | ALIROCUMAB | Treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | primary hypercholesterolaemia | 238076009 | Primary hypercholesterolaemia | ALIROCUMAB | CARDIOLOGY | CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY |
| 1682 | ALITRETINOIN | Severe chronic hand eczema | TA177 | hand eczema | 238556009 | Psoriasiform hand eczema | ALITRETINOIN | DERMATOLOGY | DERMATOLOGY |
| 1683 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 134405005 | Suspected breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1684 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 160287004 | FH: Breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1685 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 268547008 | Screening for breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1686 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 405823003 | Breast cancer 1, early onset gene mutation carrier detection test | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1687 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 429740004 | Family history of breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1688 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 431330007 | Family history of breast cancer 1 gene mutation | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1689 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 431331006 | Family history of breast cancer 2 gene mutation | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1690 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 706970001 | TNBC - Triple-negative breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1691 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 94361000000105 | Breast cancer detected by national screening programme | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1692 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 143691000119102 | Family history of breast cancer gene mutation in first degree relative | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1693 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 276341000000100 | Fast track referral for suspected breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1694 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 382431000000103 | Seen in fast track suspected breast cancer clinic | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1695 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 836761000000105 | National Cancer Institute breast cancer risk assessment tool | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1696 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 838351000000107 | Education about risk of breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1697 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 874291000000100 | QCancer breast cancer risk | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1698 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 895171000000104 | Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1699 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 919701000000100 | No FH of breast cancer meeting NICE CG164 referral criteria | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1700 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 1034381000000107 | Discharge from secondary care breast cancer service | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1701 | ALPELISIB WITH FULVESTRANT | Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | breast cancer | 1035841000000108 | Lymphoedema following breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1702 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 134405005 | Suspected breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1703 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 160287004 | FH: Breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1704 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 268547008 | Screening for breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1705 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 405823003 | Breast cancer 1, early onset gene mutation carrier detection test | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1706 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 429740004 | Family history of breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1707 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 431330007 | Family history of breast cancer 1 gene mutation | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1708 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 431331006 | Family history of breast cancer 2 gene mutation | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1709 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 706970001 | TNBC - Triple-negative breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1710 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 94361000000105 | Breast cancer detected by national screening programme | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1711 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 143691000119102 | Family history of breast cancer gene mutation in first degree relative | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1712 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 276341000000100 | Fast track referral for suspected breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1713 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 382431000000103 | Seen in fast track suspected breast cancer clinic | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1714 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 836761000000105 | National Cancer Institute breast cancer risk assessment tool | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1715 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 838351000000107 | Education about risk of breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1716 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 874291000000100 | QCancer breast cancer risk | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1717 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 895171000000104 | Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1718 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 919701000000100 | No FH of breast cancer meeting NICE CG164 referral criteria | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1719 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 1034381000000107 | Discharge from secondary care breast cancer service | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1720 | ALPELISIB WITH FULVESTRANT | Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer | TA652 | breast cancer | 1035841000000108 | Lymphoedema following breast cancer | ALPELISIB | MEDICAL ONCOLOGY | MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY |
| 1721 | ALTEPLASE | Ischaemic stroke (acute) | TA122 | ischaemic stroke | 422504002 | Ischaemic stroke | ALTEPLASE | STROKE MEDICINE | STROKE MEDICINE|NEUROLOGY |
| 1722 | ALTEPLASE | Ischaemic stroke (acute) | TA264 | ischaemic stroke | 422504002 | Ischaemic stroke | ALTEPLASE | STROKE MEDICINE | STROKE MEDICINE|NEUROLOGY |
| 1723 | ALTEPLASE | Ischaemic stroke (acute) | TA122 | ischaemic stroke | 788880006 | Cerebral ischaemic stroke due to dissection of artery | ALTEPLASE | STROKE MEDICINE | STROKE MEDICINE|NEUROLOGY |
| 1724 | ALTEPLASE | Ischaemic stroke (acute) | TA264 | ischaemic stroke | 788880006 | Cerebral ischaemic stroke due to dissection of artery | ALTEPLASE | STROKE MEDICINE | STROKE MEDICINE|NEUROLOGY |
| 1725 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 1755008 | Healed myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1726 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 15990001 | Acute myocardial infarction of posterolateral wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1727 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 22298006 | MI - myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1728 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 41380003 | Radioisotope scan for myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1729 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 52035003 | Acute anteroapical myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1730 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 54329005 | Acute anterior myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1731 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 57054005 | Acute myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1732 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 58612006 | Acute myocardial infarction of lateral wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1733 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 62695002 | Acute anteroseptal myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1734 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 65547006 | Acute inferolateral myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1735 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 66189004 | Postmyocardial infarction syndrome | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1736 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 70211005 | Acute anterolateral myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1737 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 73795002 | Acute myocardial infarction of diaphragmatic wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1738 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 76593002 | Acute myocardial infarction of inferoposterior wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1739 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 79009004 | Acute myocardial infarction of septum | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1740 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 129574000 | Postoperative myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1741 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 160361002 | FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]) | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1742 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 164866006 | Electrocardiogram: no myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1743 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 164867002 | Electrocardiographic old myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1744 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194809007 | Acute myocardial infarction of atrium | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1745 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194821006 | Aborted myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1746 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194856005 | Subsequent myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1747 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194857001 | Subsequent myocardial infarction of anterior wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1748 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194858006 | Subsequent myocardial infarction of inferior wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1749 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194862000 | Hemopericardium due to and following acute myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1750 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194863005 | Atrial septal defect due to and following acute myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1751 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194865003 | Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1752 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 194868001 | Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1753 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233838001 | Acute posterior myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1754 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233839009 | Old anterior myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1755 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233840006 | Old inferior myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1756 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233841005 | Old lateral myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1757 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233842003 | Old posterior myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1758 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233843008 | Silent myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1759 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233847009 | Cardiac rupture due to and following acute myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1760 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 233885007 | Pericarditis following myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1761 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 266288001 | Myocardial infarction (& [acute]) or coronary thrombosis | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1762 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 266897007 | Family history of myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1763 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 275122004 | Family history: Myocardial infarction at less than 60 | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1764 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 275123009 | Family history: Myocardial infarction at greater than 60 | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1765 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 304914007 | Acute Q wave myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1766 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 308065005 | History of myocardial infarction in last year | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1767 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 311793000 | Postoperative transmural myocardial infarction of inferior wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1768 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 311796008 | Postoperative subendocardial myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1769 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 314207007 | Non-Q wave myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1770 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 315619001 | Family history of myocardial infarction in male relative of first degree, age known | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1771 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 315620007 | Family history of myocardial infarction in male relative of first degree, age unknown | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1772 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 315621006 | Family history of myocardial infarction in female relative of first degree, age known | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1773 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 315622004 | Family history of myocardial infarction in female relative of first degree, age unknown | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1774 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 394710008 | First myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1775 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 399211009 | Previous myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1776 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 401303003 | STEMI - ST elevation myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1777 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 401314000 | Acute non-ST segment elevation myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1778 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 698593009 | History of non-ST segment elevation myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1779 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 703164000 | Acute anterior ST segment elevation myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1780 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 703213009 | Acute STEMI (ST elevation myocardial infarction) of inferior wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1781 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 827164008 | Delayed postmyocardial infarction syndrome | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1782 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 879955009 | MINOCA - myocardial infarction with non-obstructive coronary artery | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1783 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 515711000000105 | Family history of myocardial infarction in second degree relative less than 50 years | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1784 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 515741000000106 | Family history of myocardial infarction in first degree relative less than 60 years | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1785 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 715971000000103 | Excepted from myocardial infarction quality indicators - informed dissent | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1786 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 715981000000101 | Excepted from myocardial infarction quality indicators - patient unsuitable | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1787 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 717541000000106 | Exception reporting - myocardial infarction quality indicators | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1788 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 883961000000109 | Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1789 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 12238111000119106 | Acute ST segment elevation myocardial infarction of inferolateral wall | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1790 | ALTEPLASE | Myocardial infarction | TA052 | myocardial infarction | 16837681000119104 | Myocardial infarction due to demand ischaemia | ALTEPLASE | CARDIOLOGY | CARDIOLOGY |
| 1791 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 6142004 | Influenza | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1792 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 24662006 | Influenza caused by Influenza B virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1793 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 41269000 | Influenzal bronchopneumonia | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1794 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 44470000 | Haemophilus influenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1795 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 46233009 | Influenza virus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1796 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 51593004 | Haemophilus parainfluenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1797 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 64917006 | Pneumonia due to parainfluenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1798 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 70036007 | Haemophilus influenzae pneumonia | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1799 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 74644004 | Influenza with encephalopathy | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1800 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 86198006 | Administration of vaccine product containing only Influenza virus antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1801 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 89117003 | Parainfluenza virus type 4 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1802 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 91428005 | Haemophilus influenzae infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1803 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 95891005 | Influenza-like illness | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1804 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 120753009 | Influenza A virus antibody | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1805 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 120843002 | Influenza B virus Ab | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1806 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 120975003 | Haemophilus influenzae type b antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1807 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 127787002 | Haemophilus influenzae type b immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1808 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170343007 | First Haemophilus influenzae type b vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1809 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170344001 | Administration of second dose of Haemophilus influenzae type b vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1810 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170345000 | Third Haemophilus influenzae type b vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1811 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170346004 | Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1812 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170428009 | First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1813 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170429001 | Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1814 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 170430006 | Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1815 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 171272004 | No consent - influenza immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1816 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 171282003 | Influenza immunization advised at home | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1817 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 171290003 | Influenza vaccination consent given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1818 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 171291004 | No consent for Haemophilus influenzae type b immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1819 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 185900003 | Has influenza vaccination at home | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1820 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 185901004 | Has influenza vaccination at surgery | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1821 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 185902006 | Has influenza vaccination at hospital | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1822 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 185903001 | Needs influenza immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1823 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 192721000 | Post influenza vaccination encephalitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1824 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 194946005 | Acute myocarditis - influenzal | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1825 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195721005 | Acute bronchitis caused by Haemophilus influenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1826 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195726000 | Acute parainfluenza virus bronchitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1827 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195878008 | Pneumonia and influenza | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1828 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195923003 | Influenza with laryngitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1829 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195924009 | Influenza with pharyngitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1830 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195929004 | Influenza with gastrointestinal tract involvement | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1831 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 195931008 | Influenza like illness | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1832 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 234558001 | Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1833 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 266393000 | Influenza-like illness | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1834 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 268561003 | Influenza immunization advised in surgery | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1835 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 275983007 | Influenza immunisation advised | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1836 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 291749008 | Influenza vaccine poisoning | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1837 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 293112000 | Influenza split virion vaccine adverse reaction | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1838 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 293113005 | Influenza surface antigen vaccine adverse reaction | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1839 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 293127000 | Adverse reaction to Haemophilus influenzae type b vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1840 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 294647003 | Allergy to influenza vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1841 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 294648008 | Allergy to influenza split virion vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1842 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 294649000 | Allergy to influenza surface antigen vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1843 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 294664000 | Haemophilus influenzae type b vaccine allergy | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1844 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 308532005 | Influenza vaccination status | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1845 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 309789002 | Encephalitis caused by Influenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1846 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 310306005 | First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1847 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 310307001 | Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1848 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 310308006 | Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1849 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 312870000 | Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1850 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 313383003 | Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1851 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 315640000 | Influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1852 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 315641001 | Influenza vaccination invitation letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1853 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 390796006 | Influenza vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1854 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 396425006 | FLU - Influenza vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1855 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407479009 | Influenza A virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1856 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407480007 | Influenza B virus(B/Lee/40) | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1857 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407489008 | Human parainfluenza virus 1 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1858 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407491000 | Parainfluenza virus type 2 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1859 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407493002 | Human parainfluenza virus 3 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1860 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407498006 | Human parainfluenza viruses | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1861 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407573008 | Influenza vaccination not indicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1862 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 407598009 | No consent for third Haemophilus influenzae type b vaccine booster | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1863 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 413103005 | Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1864 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 413105003 | Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1865 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 413106002 | Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1866 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 414001002 | Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1867 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 414259000 | First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1868 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 414496007 | Influenza vaccination telephone invite | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1869 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 415507003 | Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1870 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 415712004 | Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1871 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 416928007 | Has influenza vaccination at work | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1872 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 420113004 | Adverse reaction to component of vaccine product containing Influenza virus antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1873 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 428975001 | Haemophilus influenzae type b and meningitis C immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1874 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 441043003 | Influenza A virus subtype H1 present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1875 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 441049004 | Influenza A virus subtype H3 present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1876 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 441343005 | Influenza A virus subtype H5 present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1877 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 441344004 | Human parainfluenza virus present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1878 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 441345003 | Influenza B virus present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1879 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 442438000 | Influenza caused by Influenza A virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1880 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 442696006 | Influenza A (H1N1) swine flu | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1881 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 444426005 | Swine influenza contact | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1882 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 447685007 | Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1883 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 473169009 | History of influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1884 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 698353005 | Requires influenza virus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1885 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 698950001 | Influenza A virus subtype H1N1 vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1886 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 709410003 | Hib (Haemophilus influenzae type b) infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1887 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 711330007 | Influenza A virus subtype H1N1 detected | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1888 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 711334003 | Influenza A virus H1N1 subtype not detected | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1889 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 712833000 | Second Haemophilus influenzae type b and meningitis C vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1890 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 712834006 | First Haemophilus influenzae type b and meningitis C immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1891 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 719886001 | Haemophilus influenzae type b vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1892 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 736818002 | Influenza vaccination requested | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1893 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 737041000 | Influenza immunisation telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1894 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 770608009 | Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1895 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 770616000 | First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1896 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 770617009 | Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1897 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 770618004 | Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1898 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 787016008 | Administration of influenza vaccine via nasal route | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1899 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1162640003 | Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1900 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 61811000000102 | Hib (haemophilus influenzae type B) and meningitis C vaccination not done | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1901 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 63281000000106 | First intranasal seasonal influenza vaccination not done | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1902 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 73701000119109 | Vaccination for influenza given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1903 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 88381000000109 | No consent for 2nd HIB (haemophilus influenzae type B) booster | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1904 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 135221000119101 | Influenza A H1N1 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1905 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 166311000000109 | Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1906 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 199331000000106 | Did not attend influenza vaccination appointment | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1907 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 200481000000107 | Influenza vaccination invitation first letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1908 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 200491000000109 | Influenza vaccination invitation second letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1909 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 200501000000103 | Influenza vaccination invitation third letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1910 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 201391000000106 | Booster influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1911 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 202301000000106 | First pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1912 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 202311000000108 | Second pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1913 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 299161000000100 | Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1914 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 310551000000106 | Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1915 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 335051000000104 | Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1916 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 379241000000107 | Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1917 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 380271000000101 | Consent given for pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1918 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 380381000000108 | Pandemic influenza vaccination refused | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1919 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 380631000000100 | Pandemic influenza vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1920 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 380741000000101 | First pandemic influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1921 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 380771000000107 | Second pandemic influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1922 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 380801000000105 | Pandemic influenza vaccination not indicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1923 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 505251000000100 | Suspected influenza A virus subtype H1N1 infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1924 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 506751000000104 | Possible influenza A virus H1N1 subtype | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1925 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 506901000000103 | Close contact with Influenza A virus subtype H1N1 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1926 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 511571000000106 | Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1927 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 511781000000101 | Advice given about Influenza A virus subtype H1N1 infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1928 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515281000000108 | PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1929 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515291000000105 | CELVAPAN - first influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1930 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515301000000109 | PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1931 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515321000000100 | CELVAPAN - second influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1932 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515331000000103 | CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1933 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515341000000107 | PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1934 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515351000000105 | CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1935 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515361000000108 | PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1936 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 515371000000101 | No consent for influenza A (H1N1v) 2009 vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1937 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 516101000000103 | No response to influenza vaccination invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1938 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 518961000000102 | Consent given for influenza A subtype H1N1 vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1939 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 519421000000105 | Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1940 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 540151000000108 | Pneumonia or influenza NOS | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1941 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 711301000000108 | Influenza vaccination invitation SMS (short message service) text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1942 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 711831000000107 | High priority for influenza A subtype H1N1 vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1943 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 761311000000109 | Influenza vaccination verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1944 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 764141000000106 | Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1945 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 774801000000105 | Influenza A virus subtype H1N1 vaccination invitation short message service text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1946 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 777791000000102 | Influenza vaccination invitation first text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1947 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 777831000000109 | Influenza vaccination invitation second short message service text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1948 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 777851000000102 | Influenza vaccination invitation third SMS (short message service) text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1949 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 822851000000102 | Seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1950 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 822931000000100 | Seasonal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1951 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 822951000000107 | Seasonal influenza vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1952 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 822971000000103 | Seasonal influenza vaccination not indicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1953 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 822991000000104 | Consent given for seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1954 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 844941000000103 | Influenza vaccination invitation email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1955 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 844961000000102 | Influenza vaccination invitation first email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1956 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 844981000000106 | Influenza vaccination invitation second email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1957 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 845001000000101 | Influenza vaccination invitation third email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1958 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 860151000000103 | Influenza vaccination first verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1959 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 860171000000107 | Influenza vaccination second verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1960 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 860211000000105 | Influenza vaccination second telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1961 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 860291000000101 | Influenza vaccination third verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1962 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 868241000000109 | Administration of intranasal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1963 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 868491000000103 | No consent for seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1964 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 871521000000104 | First intranasal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1965 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 871541000000106 | Second intranasal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1966 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 871751000000104 | Administration of first intranasal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1967 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 871781000000105 | Administration of second intranasal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1968 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 873681000000101 | Provision of information about seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1969 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 882141000000100 | Did not attend second intranasal seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1970 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 882181000000108 | Did not attend first intranasal seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1971 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 884821000000108 | Administration of first intranasal pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1972 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 884841000000101 | Administration of second intranasal pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1973 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 884861000000100 | Administration of first intranasal seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1974 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 884881000000109 | Administration of second intranasal seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1975 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 884901000000107 | First intranasal pandemic influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1976 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 884921000000103 | Second intranasal pandemic influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1977 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 885971000000103 | First intranasal seasonal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1978 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 885991000000104 | First intranasal pandemic influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1979 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 886011000000103 | Second intranasal seasonal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1980 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 886071000000108 | Did not attend first intranasal pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1981 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 886111000000102 | Did not attend second intranasal pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1982 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 897331000000109 | Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1983 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 898291000000101 | DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1984 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 913961000000102 | Education about influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1985 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 932221000000103 | At risk of influenza related complication | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1986 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 935351000000106 | Long term indication for seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1987 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 945831000000105 | First intramuscular seasonal influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1988 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955641000000103 | Influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1989 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955651000000100 | Seasonal influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1990 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955661000000102 | First intranasal seasonal influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1991 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955671000000109 | Second intramuscular seasonal influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1992 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955681000000106 | Second intranasal seasonal influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1993 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955691000000108 | Seasonal influenza vaccination given by pharmacist | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1994 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 955701000000108 | Seasonal influenza vaccination given while hospital inpatient | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1995 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 985151000000100 | Administration of first inactivated seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1996 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 985171000000109 | Administration of second inactivated seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1997 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 996211000000100 | Influenza (A and B) serology | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1998 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 996761000000106 | Haemophilus influenzae B IgG level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 1999 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1001341000000106 | Influenza A antigen level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2000 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1001351000000109 | Influenza B antigen level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2001 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1005101000000108 | Parainfluenza virus antibody level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2002 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1005111000000105 | Parainfluenza type 3 antibody level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2003 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1008161000000101 | Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2004 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1008171000000108 | Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2005 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1008181000000105 | Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2006 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1008251000000105 | Influenza B virus ribonucleic acid detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2007 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1008261000000108 | Influenza A virus ribonucleic acid detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2008 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1008771000000107 | Haemophilus influenzae B antibody level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2009 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1010721000000107 | Avian influenza virus RNA (ribonucleic acid) detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2010 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1014261000000103 | Influenza A antibody level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2011 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1014271000000105 | Influenza B antibody level | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2012 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1020381000000100 | Parainfluenza virus antigen assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2013 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1029731000000105 | Parainfluenza type 1 nucleic acid detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2014 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1031631000000102 | Avian influenza virus nucleic acid detection assay | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2015 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1033051000000101 | Influenza due to zoonotic influenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2016 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1033071000000105 | Influenza due to pandemic influenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2017 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1033091000000109 | Influenza due to seasonal influenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2018 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1033111000000104 | Influenza with pneumonia due to seasonal influenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2019 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1037311000000106 | First intranasal seasonal influenza vaccination given by pharmacist | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2020 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1037331000000103 | Second intranasal seasonal influenza vaccination given by pharmacist | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2021 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1037351000000105 | First inactivated seasonal influenza vaccination given by pharmacist | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2022 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1037371000000101 | Second inactivated seasonal influenza vaccination given by pharmacist | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2023 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1066171000000108 | Seasonal influenza vaccination given by midwife | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2024 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1066181000000105 | First inactivated seasonal influenza vaccination given by midwife | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2025 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1066191000000107 | Second inactivated seasonal influenza vaccination given by midwife | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2026 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1082431000000104 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2027 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1082441000000108 | First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2028 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1082451000000106 | Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2029 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1082461000000109 | Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2030 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1082521000000100 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2031 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1083421000000107 | Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2032 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1086431000000100 | First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2033 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1086441000000109 | Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2034 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1086451000000107 | Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2035 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1095821000000105 | Influenza vaccination first telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2036 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1095831000000107 | Influenza vaccination second telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2037 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1095841000000103 | Influenza vaccination third telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2038 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1239861000000100 | Seasonal influenza vaccination given in school | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2039 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1484821000000104 | Influenza vaccination invitation short message service text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2040 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1484831000000102 | Influenza vaccination invitation first SMS (short message service) text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2041 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1484841000000106 | Influenza vaccination invitation second SMS (short message service) text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2042 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 1484851000000109 | Influenza vaccination invitation third short message service text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2043 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 2427211000000109 | Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2044 | AMANTADINE | Influenza (post-exposure prophylaxis) | TA158 | influenza | 3244411000001106 | Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur) | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2045 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 6142004 | Influenza | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2046 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 24662006 | Influenza caused by Influenza B virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2047 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 41269000 | Influenzal bronchopneumonia | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2048 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 44470000 | Haemophilus influenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2049 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 46233009 | Influenza virus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2050 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 51593004 | Haemophilus parainfluenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2051 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 64917006 | Pneumonia due to parainfluenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2052 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 70036007 | Haemophilus influenzae pneumonia | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2053 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 74644004 | Influenza with encephalopathy | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2054 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 86198006 | Administration of vaccine product containing only Influenza virus antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2055 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 89117003 | Parainfluenza virus type 4 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2056 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 91428005 | Haemophilus influenzae infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2057 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 95891005 | Influenza-like illness | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2058 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 120753009 | Influenza A virus antibody | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2059 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 120843002 | Influenza B virus Ab | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2060 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 120975003 | Haemophilus influenzae type b antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2061 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 127787002 | Haemophilus influenzae type b immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2062 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170343007 | First Haemophilus influenzae type b vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2063 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170344001 | Administration of second dose of Haemophilus influenzae type b vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2064 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170345000 | Third Haemophilus influenzae type b vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2065 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170346004 | Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2066 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170428009 | First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2067 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170429001 | Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2068 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 170430006 | Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2069 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 171272004 | No consent - influenza immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2070 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 171282003 | Influenza immunization advised at home | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2071 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 171290003 | Influenza vaccination consent given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2072 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 171291004 | No consent for Haemophilus influenzae type b immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2073 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 185900003 | Has influenza vaccination at home | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2074 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 185901004 | Has influenza vaccination at surgery | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2075 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 185902006 | Has influenza vaccination at hospital | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2076 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 185903001 | Needs influenza immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2077 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 192721000 | Post influenza vaccination encephalitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2078 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 194946005 | Acute myocarditis - influenzal | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2079 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195721005 | Acute bronchitis caused by Haemophilus influenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2080 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195726000 | Acute parainfluenza virus bronchitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2081 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195878008 | Pneumonia and influenza | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2082 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195923003 | Influenza with laryngitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2083 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195924009 | Influenza with pharyngitis | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2084 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195929004 | Influenza with gastrointestinal tract involvement | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2085 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 195931008 | Influenza like illness | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2086 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 234558001 | Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2087 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 266393000 | Influenza-like illness | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2088 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 268561003 | Influenza immunization advised in surgery | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2089 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 275983007 | Influenza immunisation advised | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2090 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 291749008 | Influenza vaccine poisoning | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2091 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 293112000 | Influenza split virion vaccine adverse reaction | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2092 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 293113005 | Influenza surface antigen vaccine adverse reaction | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2093 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 293127000 | Adverse reaction to Haemophilus influenzae type b vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2094 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 294647003 | Allergy to influenza vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2095 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 294648008 | Allergy to influenza split virion vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2096 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 294649000 | Allergy to influenza surface antigen vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2097 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 294664000 | Haemophilus influenzae type b vaccine allergy | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2098 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 308532005 | Influenza vaccination status | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2099 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 309789002 | Encephalitis caused by Influenza virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2100 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 310306005 | First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2101 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 310307001 | Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2102 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 310308006 | Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2103 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 312870000 | Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2104 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 313383003 | Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2105 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 315640000 | Influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2106 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 315641001 | Influenza vaccination invitation letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2107 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 390796006 | Influenza vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2108 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 396425006 | FLU - Influenza vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2109 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407479009 | Influenza A virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2110 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407480007 | Influenza B virus(B/Lee/40) | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2111 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407489008 | Human parainfluenza virus 1 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2112 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407491000 | Parainfluenza virus type 2 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2113 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407493002 | Human parainfluenza virus 3 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2114 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407498006 | Human parainfluenza viruses | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2115 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407573008 | Influenza vaccination not indicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2116 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 407598009 | No consent for third Haemophilus influenzae type b vaccine booster | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2117 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 413103005 | Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2118 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 413105003 | Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2119 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 413106002 | Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2120 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 414001002 | Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2121 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 414259000 | First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2122 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 414496007 | Influenza vaccination telephone invite | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2123 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 415507003 | Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2124 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 415712004 | Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2125 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 416928007 | Has influenza vaccination at work | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2126 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 420113004 | Adverse reaction to component of vaccine product containing Influenza virus antigen | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2127 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 428975001 | Haemophilus influenzae type b and meningitis C immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2128 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 441043003 | Influenza A virus subtype H1 present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2129 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 441049004 | Influenza A virus subtype H3 present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2130 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 441343005 | Influenza A virus subtype H5 present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2131 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 441344004 | Human parainfluenza virus present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2132 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 441345003 | Influenza B virus present | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2133 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 442438000 | Influenza caused by Influenza A virus | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2134 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 442696006 | Influenza A (H1N1) swine flu | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2135 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 444426005 | Swine influenza contact | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2136 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 447685007 | Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2137 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 473169009 | History of influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2138 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 698353005 | Requires influenza virus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2139 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 698950001 | Influenza A virus subtype H1N1 vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2140 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 709410003 | Hib (Haemophilus influenzae type b) infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2141 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 711330007 | Influenza A virus subtype H1N1 detected | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2142 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 711334003 | Influenza A virus H1N1 subtype not detected | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2143 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 712833000 | Second Haemophilus influenzae type b and meningitis C vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2144 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 712834006 | First Haemophilus influenzae type b and meningitis C immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2145 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 719886001 | Haemophilus influenzae type b vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2146 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 736818002 | Influenza vaccination requested | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2147 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 737041000 | Influenza immunisation telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2148 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 770608009 | Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2149 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 770616000 | First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2150 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 770617009 | Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2151 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 770618004 | Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2152 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 787016008 | Administration of influenza vaccine via nasal route | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2153 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 1162640003 | Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2154 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 61811000000102 | Hib (haemophilus influenzae type B) and meningitis C vaccination not done | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2155 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 63281000000106 | First intranasal seasonal influenza vaccination not done | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2156 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 73701000119109 | Vaccination for influenza given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2157 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 88381000000109 | No consent for 2nd HIB (haemophilus influenzae type B) booster | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2158 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 135221000119101 | Influenza A H1N1 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2159 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 166311000000109 | Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2160 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 199331000000106 | Did not attend influenza vaccination appointment | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2161 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 200481000000107 | Influenza vaccination invitation first letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2162 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 200491000000109 | Influenza vaccination invitation second letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2163 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 200501000000103 | Influenza vaccination invitation third letter sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2164 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 201391000000106 | Booster influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2165 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 202301000000106 | First pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2166 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 202311000000108 | Second pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2167 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 299161000000100 | Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2168 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 310551000000106 | Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2169 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 335051000000104 | Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2170 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 379241000000107 | Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2171 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 380271000000101 | Consent given for pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2172 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 380381000000108 | Pandemic influenza vaccination refused | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2173 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 380631000000100 | Pandemic influenza vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2174 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 380741000000101 | First pandemic influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2175 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 380771000000107 | Second pandemic influenza vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2176 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 380801000000105 | Pandemic influenza vaccination not indicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2177 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 505251000000100 | Suspected influenza A virus subtype H1N1 infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2178 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 506751000000104 | Possible influenza A virus H1N1 subtype | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2179 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 506901000000103 | Close contact with Influenza A virus subtype H1N1 | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2180 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 511571000000106 | Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2181 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 511781000000101 | Advice given about Influenza A virus subtype H1N1 infection | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2182 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515281000000108 | PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2183 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515291000000105 | CELVAPAN - first influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2184 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515301000000109 | PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2185 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515321000000100 | CELVAPAN - second influenza A (H1N1v) 2009 vaccination given | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2186 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515331000000103 | CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2187 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515341000000107 | PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2188 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515351000000105 | CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2189 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515361000000108 | PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2190 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 515371000000101 | No consent for influenza A (H1N1v) 2009 vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2191 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 516101000000103 | No response to influenza vaccination invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2192 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 518961000000102 | Consent given for influenza A subtype H1N1 vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2193 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 519421000000105 | Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2194 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 540151000000108 | Pneumonia or influenza NOS | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2195 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 711301000000108 | Influenza vaccination invitation SMS (short message service) text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2196 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 711831000000107 | High priority for influenza A subtype H1N1 vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2197 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 761311000000109 | Influenza vaccination verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2198 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 764141000000106 | Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2199 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 774801000000105 | Influenza A virus subtype H1N1 vaccination invitation short message service text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2200 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 777791000000102 | Influenza vaccination invitation first text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2201 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 777831000000109 | Influenza vaccination invitation second short message service text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2202 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 777851000000102 | Influenza vaccination invitation third SMS (short message service) text message sent | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2203 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 822851000000102 | Seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2204 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 822931000000100 | Seasonal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2205 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 822951000000107 | Seasonal influenza vaccination contraindicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2206 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 822971000000103 | Seasonal influenza vaccination not indicated | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2207 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 822991000000104 | Consent given for seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2208 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 844941000000103 | Influenza vaccination invitation email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2209 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 844961000000102 | Influenza vaccination invitation first email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2210 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 844981000000106 | Influenza vaccination invitation second email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2211 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 845001000000101 | Influenza vaccination invitation third email | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2212 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 860151000000103 | Influenza vaccination first verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2213 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 860171000000107 | Influenza vaccination second verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2214 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 860211000000105 | Influenza vaccination second telephone invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2215 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 860291000000101 | Influenza vaccination third verbal invitation | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2216 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 868241000000109 | Administration of intranasal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2217 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 868491000000103 | No consent for seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2218 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 871521000000104 | First intranasal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2219 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 871541000000106 | Second intranasal influenza vaccination declined | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2220 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 871751000000104 | Administration of first intranasal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2221 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 871781000000105 | Administration of second intranasal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2222 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 873681000000101 | Provision of information about seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2223 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 882141000000100 | Did not attend second intranasal seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2224 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 882181000000108 | Did not attend first intranasal seasonal influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2225 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 884821000000108 | Administration of first intranasal pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEASES|GENERAL MEDICINE |
| 2226 | AMANTADINE | Influenza (prevention) | TA067 | influenza | 884841000000101 | Administration of second intranasal pandemic influenza vaccination | AMANTADINE | INFECTIOUS DISEASES | INFECTIOUS DISEAS |
| The file is too large to be shown. View Raw |